Viveve Medical (VIVE) Stock Is Rocketing On Positive Clinical Data

Viveve Medical VIVE Stock News

Viveve Medical Inc (NASDAQ: VIVE) is making a run for the top in the market this morning after the company announced positive clinical data. The positive data seems to be sending the shorts running for cover, leading to gains of more than 100%. Here’s what’s going on:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

VIVE Stock Rockets On Positive Clinical Data

In the press release, Viveve Medical announced positive data from a three-arm, five-month Stress Urinary Incontinence (SUI) feasibility study. During the study, the company compared its Cryogen-cooled Monopolar Radiofrequency treatment and a cryogen-only sham treatment to an inert sham treatment as potential options in mild to moderate SUI in women.

The data from the trial proved be be positive.In the release, the company said that it achieved all of its primary and secondary endpoints, with its cryogen treatment options outperforming inert sham treatments.

Moreover, VIVE announced positive outcomes from an in-vivo preclinical study that was conducted to validate its new inert sham tip for use in the upcoming pivotal PURSUIT Trial.

In a statement, Scott Durbin, CEO at VIVE, had the following to offer:

We are extraordinarily pleased to report positive results from our 3-arm SUI feasibility study, as well as our in-vivo preclinical study. We believe the combined results from both of these studies support our thesis that the cryogen-cooling treatment tip, used as a sham treatment in our prior LIBERATE-International SUI trial, was likely producing a positive therapeutic effect. The fact that we now have a true inert sham treatment tip provides us more confidence that our upcoming pivotal PURSUIT Trial can achieve its primary efficacy endpoint and position Viveve for a potential SUI indication in the United States.

This Is Huge News

At the end of the day, the news released by Viveve Medical proved to be overwhelmingly positive. The company is on the verge of a pivotal trial, and producing positive data all the way there.

The SUI market is a massive one, and it’s growing. In fact, it’s expected that by 2023, the market will be worth more than $3.4 billion annually. Considering the fact that VIVE stock trades with a market cap of under $20 million, should the company break into this market, it would prove to be a massive opportunity.

Considering the positive data released today, and coming pivotal United States trial, the company is well on its way to bringing this goal to fruition, making VIVE stock one to watch closely.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story

Join our free mailing list below to receive real-time news alerts!

Subscribe Today!

* indicates required

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.